HYDERABAD, India (December 16, 2014) — Daicel Corporation, the global leader in chiral chromatography, today announced the results of a successful technical collaboration between its Indian subsidiary Daicel Chiral Technologies India (DCTI) and Laurus Labs, a leading API manufacturer in India. DCTI has successfully developed a cost-effective commercial-scale SMB separation process for a chiral generic drug. The separation process utilizes single solvent elution on a Daicel Chiral Stationary Phase.
“We are happy to collaborate with DCTI, which is located in close proximity of our R & D facility. DCTI has developed an outstanding continuous chromatography process for our API. Thus we quickly realized our dream of implementing commercial scale SMB separation technology for our product, thanks to Daicel innovations in chiral chromatography,” said Dr. SatyanarayanaChava, CEO of Laurus Labs.
“It is rewarding to see that Laurus has a passion to implement SMB technology for commercial production of generic APIs. We are glad to be partnering with Laurus to prove that SMB is also a viable option for generic API production,” said Mr. Dieter Heckmann,executive officer, Daicel Corporation, Japan.
“This example suggests that the SMB option should be explored to assess the cost benefit analysis over traditional processes,” said Mr. Lakshmi Narayana, vice president of DCTI. “Our collaboration will continue to generate SMB POC studies for various intermediates and APIs in Laurus’ portfolio.” CCI Newswire
